Abstract: Bis-amide inhibitors of SARS-CoV-2 (COVID), pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.

Abstract: Bis-amide inhibitors of SARS-CoV-2 (COVID), pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.

Abstract: Compounds of formula (I), pharmaceutical compositions comprising compounds of the formula (I), and methods of treating an HIV infection comprising administering an effective amount of one or more compounds of formula (I), or a pharmaceutical composition comprising same.

Abstract: A method for manufacturing bleached pulp from a feedstock that includes recycled paper. The method includes steps of: (1) impregnating the feedstock with cooking liquor to yield an impregnated material having a liquor-to-fiber mass ratio of at most about 4:1; (2) cooking the impregnated material to remove at least a portion of the lignin within the impregnated material, thereby yielding a cooked pulp; and (3) bleaching the cooked pulp.

Abstract: Bis-amide inhibitors of SARS-CoV-2 (COVID); pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.

Abstract: Inhibitors of SARS-CoV-2 (COVID), pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.

Abstract: Described herein are compounds of the formulae (I)-(III) as well as pharmaceutical compositions comprising such compounds and methods for using such compounds/pharmaceutical compositions for treating Alzheimer's disease.

Abstract: Various embodiments of the present invention are directed to compounds of the formula (I) or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof. The compounds disclosed herein are as inhibitors of HIV-1 protease and, as a result, are useful in the treatment of HIV infection.

Abstract: Embodiments of apparatuses and methods for reforming of hydrocarbons including recovery of products are provided. In one example, a method comprises separating a reforming-zone effluent into a net gas phase stream and a liquid phase hydrocarbon stream. The net gas phase stream is separated for forming an H2-rich stream and a first liquid phase hydrocarbon stream. The H2-rich stream may be contacted with an adsorbent to form an H2-ultra rich stream and a gas stream. C3/C4 hydrocarbons are absorbed from the gas stream with the liquid phase hydrocarbon stream. The gas stream may be contacted with an H2/hydrocarbon separation membrane to separate the PSA tail gas stream and form an H2-rich permeate stream and an H2 depleted non-permeate residue stream.

Abstract: A transparent proxy for malware detection includes a monitor module, a protocol determination module, a challenge generation module, a response determination module, and a data control module. The monitor module examines data originating from an application towards a remote server. The protocol determination module identifies the protocol type used for the data. The challenge generation module produces a challenge for the application based upon the protocol type, sends the challenge to the application, and maintains a state related to the data and the challenge. The response determination module makes a determination if an automatic non-interactive application response is received in response to the challenge from the application. The data control module allows the first data to continue to the remote server when the determination is valid. The data control module reports malware detection and blocks the data to continue to the remote server when the determination is invalid.

Abstract: Various embodiments relate to a compound of the formula (I) and (II), wherein X, X1, X2, X3, and R1-R4 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.

Abstract: A transparent proxy for malware detection includes a monitor module, a protocol determination module, a challenge generation module, a response determination module, and a data control module. The monitor module examines data originating from an application towards a remote server. The protocol determination module identifies the protocol type used for the data. The challenge generation module produces a challenge for the application based upon the protocol type, sends the challenge to the application, and maintains a state related to the data and the challenge. The response determination module makes a determination if an automatic non-interactive application response is received in response to the challenge from the application. The data control module allows the first data to continue to the remote server when the determination is valid. The data control module reports malware detection and blocks the data to continue to the remote server when the determination is invalid.

Abstract: Techniques for key distribution are provided. A first symmetric key is generated for a first downstream site, and a second symmetric key is generated for a second downstream site. The first symmetric key is transmitted to the first downstream site, and the second symmetric key is transmitted to the second downstream site. Upon receiving an indication that the first symmetric key was successfully deployed at the first downstream site, the first symmetric key is deployed on a first network node of an upstream site. Finally, upon determining that the second symmetric key was not successfully deployed at the second downstream site, techniques include refraining from deploying the second symmetric key to a second network node of the upstream site, where the second network node continues to communicate with the second downstream site using an original symmetric key.

Abstract: Compositions and methods for systemic delivery of at least one cargo in a vascular plant. Compositions may include at least one cargo delivery particle, having a core and a shell; and at least one cargo disposed on the shell. The core may include at least one micronutrient. The shell may include a coating material. The at least one cargo delivery particle may have a size of less than about 10 nanometers. Methods may include administering an effective amount of the compositions to a plant.

Abstract: Described herein are compounds of the formulae (I), (Ia), (Ib), and (II) and pharmaceutically acceptable salts, isomers, mixture of isomers, crystalline forms, non-crystalline forms, hydrates, or solvates thereof, as well as methods of making and using compounds of the formulae (I), (Ia), (Ib), and (II) to, among other things, treat HIV/AIDS.

Abstract: Described herein are compounds of the formulae (I)-(III) as well as pharmaceutical compositions comprising such compounds and methods for using such compounds/pharmaceutical compositions for treating Alzheimer's disease.

Abstract: Embodiments provide, among other compounds, a family of compounds that can be used as therapeutic anti-cancer agents, methods for using such compounds to treat cancer, and methods of making such compounds.

Abstract: Various embodiments relate to a compound of the formula (I) and (II), wherein X, X1, X2, X3, and R1-R4 am defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.

Abstract: Various embodiments relate to a compound of the formula (I) and (II), wherein X, X1, X2, X3, and R1-R4 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.

Abstract: An on-demand disposable virtual work system that includes: a virtual machine monitor to host virtual machines, a virtual machine pool manager, a host operating system, a host program permissions list, and a request handler module. The virtual machine pool manager manages virtual machine resources. The host operating system interfaces with a user and virtual machines created with an image of a reference operating system. The host program permissions list may be a black list and/or a white list used to indicate allowable programs. The request handler module allows execution of the program if the program is allowable. If the program is not allowable, the host request handler module: denies program execution and urges a virtual machine specified by the virtual machine pool manager to execute the program. The virtual machine is terminated when the program closes.